In vitro evaluation of a novel 2,6,9-trisubstituted purine acting as a cyclin-dependent kinase inhibitor

Annals of the New York Academy of Sciences

Volumn 886, Issue , 1999, Pages 180-182

  Giocanti, Nicole ^a   Sadri, Ramin ^a   Legraverend, Michel ^b   Ludwig, Odile ^b   Bisagni, Emile ^b   Leclerc, Sophie ^c   Meijer, Laurent ^c   Favaudon, Vincent ^a,d  

^a INSERM   (France)

^b CNRS   (France)

^c STATION BIOLOGIQUE DE ROSCOFF   (France)

^d INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN B; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; ML 1437; OLOMOUCINE; PURINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; CELL CYCLE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN;

ANIMALIA;

EID: 0033404245     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1999.tb09411.x     Document Type: Conference Paper

References (10)

1. 1. Bartkova, J., J. Lukas & J. Bartek. 1997. Aberrations of the G1-and G1/S-regulating genes in human cancer. In Progress in Cell Cycle Research, Vol. 3. L. Meijer, S. Guidet, & E.M. Philippe, Eds.: 211-220. Plenum Press. New York.
2. 2. Kitagawa, M., T. Okabe, H. Ogino et al. 1993. Butyrolactone I, a selective inhibitor of cdk2 and cdc2 kinase. Oncogene 8: 2425-2432.
3. 3. Carlson, B.A., M.M. Dubay, E.A. Sausville, L. Brizuela & P.J. Worland. 1996. Flavopiridol induces G(1) arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res. 56: 2973-2978.
4. 4. Meijer, L. & S.-H. Kim. 1997. Chemical inhibitors of cyclin-dependent kinases. Methods Enzymol. 283: 113-128.
5. 5. Vesely, J., L. Havlicek, M. Strnad et al. 1994. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224: 771-786.
6. 6. Walker, D.H., P.A. Parker & R.M. Laethem. 1998. Cell cycle arrest induced by the CDK inhibitor olomoucine protects normal, but not tumor cells, from killing by cytotoxic anticancer drugs. Proc. Am. Assoc. Cancer Res. 39: 1678.
7. 7. Maas, J.W., S. Horstmann, G.D. Borasio, J.M.H. Anneser, E.M. Shooter & P.J. Kahle. 1998. Apoptosis of central and peripheral neurons can be prevented with cyclin-dependent kinase/mitogen-activated protein kinase inhibitors. J. Neurochem. 70: 1401-1410.
8. 8. Buquet-Fagot, C., F. Lallemand, M.-N. Montagne & J. Mester. 1997. Effects of olomoucine, a selective inhibitor of cyclin-dependent kinases, on cell cycle progression in human cancer cell lines. Anti-Cancer Drugs 8: 623-631.
9. 9. Henchcliffe, C. & R.E. Burke. 1997. Increased expression of cyclin-dependent kinase 5 in induced apoptotic neuron death in rat substantia nigra. Neurosci. Lett. 230: 41-44.
10. 10. Zhang, Q., H.S. Ahuja, Z.F. Zakeri & D.J. Wolgemuth. 1997. Cyclin-dependent kinase 5 is associated with apoptotic cell death during development and tissue remodeling. Dev. Biol. 183: 222-233.